Theranostics Health Inc. is a leading provider of protein-based discovery and translational research services to drug development companies for their mechanism of action, biomarker discovery and companion diagnostic programs.
Our technologies are of particular value for companies developing Molecular Targeted Therapies and Combination Therapies due to our ability to directly measure the presence and activation status (via post-translational modifications such as phosphorylation, methylation, cleavage, etc.) of drug targets and receptors, their downstream signal transduction pathways, and potential compensatory or adaptive mechanisms within targeted cell populations.
Typically, our services are employed by pharmaceutical companies in discovery biology to assessment of preclinical candidate compounds through to proof-of-concept studies in clinical trials.
The specificity and sensitivity of our reverse-phase protein array (RPPA) technology is well suited to projects ranging from small-sized cell culture samples used for mechanism of action/efficacy studies for early stage therapeutic candidates, where compound or biologic materials may be limiting, to clinical biopsy samples or isolated immune cells where the collected biological material itself may be limiting.
Furthermore, our use of laser capture microdissection to selectively capture cell populations of interest from heterogeneous tissues allows researchers the ability to analyze biomarkers directly at the site of drug action.